<DOC>
	<DOCNO>NCT02088398</DOCNO>
	<brief_summary>This study open-label , randomize , single dose , 3-period crossover PK study . This study comprise 3 treatment period 4-day washout period . On Day -1 , subject randomize 1 6 treatment sequence . On Days 1 , 5 , 9 , subject administer Treatment A , B , C accord randomization schedule . - Treatment A : single dose 160 mg ACY-1215 CLF ( 20 mg/mL ) fed state - Treatment B : single dose 120 mg ACY-1215 ALF ( 10 mg/mL ) fed state - Treatment C : single dose 120 mg ACY-1215 ALF ( 10 mg/mL ) fast state</brief_summary>
	<brief_title>Alternative 10 mg/mL Liquid Formulation ACY 1215 ( Ricolinostat ) Healthy Subjects</brief_title>
	<detailed_description>Subjects confine Clinical Research Unit ( CRU ) time Check-in ( Day -1 ) Day 10 . Predose blood urine sample obtain prior ACY-1215 administration . Following administration ACY-1215 period , blood urine sample collect specified timepoints interval 24 hour postdose determination PK single oral dose ACY-1215 . Subjects discharge CRU Day 10 , follow completion last PK collection successful completion evaluation discharge safety test . Subjects return clinic Follow-up visit 5 7 day last dose ACY-1215 ( Days 14 16 ) additional safety evaluation .</detailed_description>
	<criteria>18 65 year age , inclusive BMI range 18.5 32.0 kg/m2 good health , determine clinically significant finding medical history , 12lead ECG , vital sign clinical laboratory evaluation , CBC , coagulation , UA negative test select drug abuse negative hepatitis panel negative HIV antibody females nonchildbearing potential outline protocol male either sterile agree use contraception outline protocol significant history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder history significant hypersensitivity , intolerance , allergy drug compound , food , substance history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug history Gilbert 's Syndrome suspicion Gilbert 's Syndrome abnormality 12lead ECG ( e.g . QTcF &gt; 450 msec , history prolong QTcinterval Brugada syndrome ) history alcoholism drug addiction within 1 year prior participation investigational study drug trial receipt investigational study drug outline protocol use prescription medications/products within 14 day ( 30 day cytochrome P450 [ CYP ] induce inhibit product outline protocol ) use overthecounter , nonprescription preparation within 14 day use tobacco nicotinecontaining product within 6 month study ; poor peripheral venous access donation blood 30 day prior Screening Followup visit acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>relative bioavailability</keyword>
	<keyword>food-effect</keyword>
</DOC>